NDAORALTABLETPriority Review
Approved
Oct 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
KALETRA (lopinavir and ritonavir) by AbbVie is hiv protease inhibitors [moa]. First approved in 2005.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KALETRA is a fixed-dose combination of lopinavir and ritonavir, two HIV protease inhibitors that work synergistically to block viral replication. Ritonavir acts as a pharmacokinetic booster, increasing lopinavir levels and efficacy. It is indicated for HIV-1 infection in treatment-experienced and treatment-naïve patients.
$0.498MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Part D spend, indicating shrinking market share and reduced commercial team investment opportunities.
Mechanism of Action
HIV Protease Inhibitors
Pharmacologic Class:
Protease Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation
Started Nov 2019
239 enrolled
HIV-1 Infection
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
Started Jun 2012
173 enrolled
Human Immunodeficiency Virus Infection
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Started Jun 2011
236 enrolled
Human Immunodeficiency Virus Infection
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
Started Jun 2011
97 enrolled
Human Immunodeficiency Virus Infection
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
Started Apr 2010
1 enrolled
HIV Infections
Worked on KALETRA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.